From June 5 to 7, 2024, the latest results of the FIM clinical implantation of MonarQTM, an innovative transcatheter tricuspid valve replacement (TTVR) system developed by Peijia Medical in collaboration with inQB8, were presented at the New York Valves (NYV, formerly TVT). The outstanding clinical results are highly encouraging and confirm the feasibility and safety of the system in successfully treating patients with severe symptomatic TR.

We expected that the clinical study of the MonarQTM TTVR system can be initiated as soon as possible in China, benefiting the large number of patients with tricuspid regurgitation, and allowing more and more patients suffering from tricuspid valve disease to benefit from advancements in valvular interventional technology.